I think the EGX merger is a great thing for this company - in the long term.
In the short term, we have more dilution, which can only lead to trading sideways, or down. The private-equity premium is now a thing of the past, and the generous price paid for Evogenix will no doubt weigh on the share price.
Until we have Phase I trial results, my price target is $1. Maybe $2 within 2-3 years.
- Forums
- ASX - By Stock
- PTD
- dilution awaits
PTD
unknown
dilution awaits
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)